Notwithstanding encouraging clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing significant difficulty from managed care entities. These companies are typically creating obstacles to access, like high cost requirements and PA that restrict consumer availability. Industry sug